Arrhythmia risk in patients with psoriasis most-read dermatology article of week

Research showing that patients with psoriasis were at increased risk of developing arrhythmia was the top-read article of the past week on Healio.com/Dermatology.

Other widely read articles focused the safety of Humira in treating patients with psoriasis and the recent FDA approval of Galderma’s antibiotic-free Epiduo Forte Gel, 0.3%/2.5%, for treatment of acne vulgaris:

Patients with psoriasis, psoriatic arthritis at greater risk for developing arrhythmia

Patients with psoriasis, and particularly those with psoriatic arthritis, were at increased risk of developing arrhythmia, independent of traditional cardiovascular risk factors, according to recently published study results.

Researchers conducted a population-based cohort study and used the Taiwan Health Insurance Research Database to identify 40,367 patients with psoriasis and 162,548 people without psoriasis from 2004 to 2006. Read more

Humira safety profile for psoriasis remains unchanged for 5 years

Humira continues to be a well-tolerated treatment, with no new safety signals observed during a 5-year review of an ongoing observational registry of patients with moderate-to-severe chronic plaque psoriasis, according to recently published research results.

Researchers collected data from ESPRIT, an ongoing 10-year observational registry, between Sept. 26, 2008, and Nov. 30, 2013. Read more

FDA approves antibiotic-free gel treatment for acne

The FDA has approved antibiotic-free Epiduo Forte Gel, 0.3%/2.5%, for once-daily, topical treatment of acne vulgaris, according to a press release from Galderma.

Jonathan Weiss

"Epiduo Forte Gel is an effective and well-tolerated antibiotic-free treatment option for the moderate to severe acne patient,” investigator Jonathan Weiss, MD, told Healio.com/Dermatology. Read more

Xeljanz might be effective as vitiligo treatment

Xeljanz was effective as treatment in a patient with vitiligo, according to recently published study results.

“This report is the first to demonstrate effective pathogenesis-based therapy for a patient with vitiligo,” the researchers concluded. “The fairly rapid response and repigmentation of the hands, which are often resistant to therapy are noteworthy.” Read more

Patients with psoriasis treated with Humira had correlation between adipokines, disease severity

Among patients with moderate-to-severe psoriasis treated with Humira, correlations were found between leptin and metabolic syndrome and inflammation, and between resistin and inflammation and disease severity, according to study results.

Researchers in Spain evaluated whether leptin and resistin, two adipokines, correlated with metabolic syndrome and disease severity in patients with psoriasis. They conducted a prospective study of 29 non-diabetic patients with moderate-to-severe psoriasis who completed therapy with Humira (adalimumab, AbbVie) for 6 months. Read more